Covance — Merger or Acquisition (November 2014)
29 slides from Covance's merger presentation, Nov 3, 2014
Slide 1: LabCorp to Acquire Covance
Filed by Laboratory Corporation of America Holdings pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Covance Inc. (Commission File No. 001-12213) The following is a slide pre
Slide 2: Forward-Looking Statement
FORWARD Cautionary This the Corporation cause aforward-looking projections “projects,” covered those stockholder approvals; integration transaction, treatments Reports The expectations. section 2document result PSLRA. foregoing communication described results of on bytheir are new of (2) “future,” m
Slide 3: Additional Information and Where to Find It
FORWARD Additional This respect proxy information Investors LabCorp In Covance Participants LabCorp, Covance’s Shareholders, regarding document participants 3described addition, communication statement/prospectus ofby may through and which Covance LabCorp’s in the atstockholders Information investor
Slide 4: Transaction Highlights
4Transaction Highlights
Slide 5: Transaction Overview: Current Terms
TRANSACTION Current Terms Transaction Equity Enterprise Implied Premium Estimated Accretion Synergies Expected Issue Financing $4.25 Strong Corporate Company Covance Headquarters David Leadership Joe Glenn Closing 5Subject Herring, 15.55 billion King, Eisenberg, value and to value LTM 32% expected s
Slide 6: Strategic Rationale: Why Are We Doing This?
STRATEGIC Creates Leading Diagnostics Enhances Profile Revenue Flows Provides LabCorp Scale Breadth Supports Covance Offerings Development Personalized with Information Investment Unique 6Innovation Data and and with Opportunity World’s of Healthcare Growth, Superior the Financial Increases and Syne
Slide 7: Providing Services from Development Through Commercialization
PROVIDING Clinical Drug Therapeutics Covance Phase Central Preclinical Informatics Risk-based Biomarker Companion Market Nutritional LabCorp Physician Commercialization Anatomic In Expanded 7Complementary Vitro Development I-IV Access Laboratory Diagnostics Trials Capabilities and Pathology/Molecula
Slide 8: Delivering Solutions for Partners
Delivering Partners Full Global, Identification Pharma Approval tracking Risk-based Early Enhanced Physicians Preferred Superior testing Payors Lower Better/faster 8Patients spectrum identification cost Improved end-to-end Expedited, Improved Clinical Needs preventive provider support, subject Uniqu
Slide 9: Combining at the Right Time: Significant Opportunities
COMBINING US ~$5.8 Hospital 15% Other Nursing Prescription and Drugs Physician 2% 27% Lab 7% Administration Costs Positive Pharma Increased Multiple Specialty Increasing Growing Opportunity *Source: 9company Health Home Testing 19% trillion* outsourcing Home Industry Care large Centers demand focus
Slide 10: Aligns with LabCorp's Capital Deployment Strategy
ALIGNS 1A Deploy To That Company’s Business Return Shareholders 2C Enhance Capabilities And Formidable Experience 3Iinformatics Improve Efficiency Compelling In chain 4F Innovation Scientific including diagnostics 5S potential Uses data Develop support Services personalized development Provides phar
Slide 11: Covance Highlights and Third Quarter Results
Covance Highlights and Third Quarter Results 11
Slide 12: Covance: The World's Most Comprehensive Drug Development Company
COVANCE: Covance Top Market-leading Expertise Industry-leading >12,500 Trial Annual Market Established Contributed 12 five activity leader Cap Revenue employees provider isinthe relationships ~$5 to biomarker THE inin the only central informatics >100 billion nutritional global >$2.5 of WORLD’S deve
Slide 13: Only Drug Development Company with a Full Range of R&D Services
ONLYSafety Pharmaceutical/Biotechnology Drug Discovery Efficacy Covance Approval 13 DRUG (NDA) Generates (IND) DEVELOPMENT More SafetyResearch and COMPANY Efficacy & Development Data WITH Than A FULL Any Other RANGE Entity OFInvolved R&D SERVICES in Drug Development
Slide 14: Market Dynamics: Pharma R&D Spend and CRO Penetration
($50 Projected 2.5% 3.1% 2.1% Pharma $CRO 2013 37% 39% 40% 42% 44% 46% Outsourced Source: 14162 158 155 151 148 145 141 137 81 76 71 67 62 58 55 in 48% 50% billions) 2014 MARKET Market 2.4% 2.2% R&D Evaluate Pharma 2015 2.3% 2.1% Clinical Size Spend 2016 DYNAMICS 2.3% Pharma R&D Development Growth 2
Slide 15: Covance Revenue Distribution
COVANCE Early (toxicology, *Central 32.8% *Phase 36.3% *Development 30.9% By Outside 46.5% U.S. 15 53.5% 63.7% Service Geography Development discovery II-IV U.S. Late-Stage Laboratory Offering REVENUE food/drug Clinical and (LTM-Sept. services) other Development (LTM-Sept. pharmacology, chemistry, 3
Slide 16: Covance Third Quarter Earnings Highlights
COVANCE ($ GAAP Restructuring Operating forma Pro Net *Diluted 16See inGain Revenues Income Income, millions Covance Operating Operating Earnings EPS, on Income Income, THIRD $66.0 Sale excluding excluding except Costs($3.2)($4.9) $627.1 press Margin, per of Margin $44.2 $76.5 excluding Business/Inv
Slide 17: Independent Surveys Rank Covance Most Preferred
INDEPENDENT 62% Baird William “Covance Morgan Covance 47% Life 17 Science vs. Equity Stanley next 23% Blair received Central is the received Strategy Research CROs and Equity clear Research Laboratory SURVEYS 9% the highest atResearch favorite for most Group 44%, (3/20/14) next North score mentions
Slide 18: Financial Highlights
Financial Highlights 18
Slide 19: Profile of Combined Company
PROFILE LTM ($ Revenue Adjusted EBITDA Operating Capital Free Strategic Accretive Earns (1) 19 inLabCorp Cash Millions) Ended cost Expenditures $5,936 acquisition Margin EBITDA1, to Cash Flow OF ofSept. Adjusted EBITDA capital COMBINED LabCorp Flow $557 $2,510 20.1% 30,by that 2$217 $774 $161 2014 E
Slide 20: Overview of Financing: Sources and Uses
OVERVIEW Uses Purchase Covance Enterprise $Transaction Investment Expected ~4.1x 206,000 Sources Debt/EBITDA Debt Cash(705) of Leverage Value Grade Expenses Covance OF250 $of FINANCING Ratings 5,630 LabCorp at $5.6 LabCorp Equity Transaction 370 Billion, $Anticipated 6,000 Cash $Debt 6,085 SOURCES 1
Slide 21: Key Terms of Contemplated Financing
4.75x KEY Revolving Bridge Principal Facility Maturity: Indicative L+125 Rates: Security: Financial TERMS 30 bps Facilities Debt/EBITDA Covenants: 21 Amount: Unsecured Yr: Max 364 Interest Credit L+125 T+195 days OF 4.75xLeverage Term CONTEMPLATED bps 5$4.3 5Yr: Unsecured bps years L+125 Loan 4.75x
Slide 22: Anticipated Financing and Debt Maturity Timeline
Anticipated FINANCING 800 1000 1200 1400 1600 1800 $2,000 $1,000 600 400 $500 02$200 Outstanding Free Expect $1 22 015 600 250 132 billion $Cash $400 $500 2016 500 $325 $1,000 to be credit Flow 2017 $Debt Debt at300 $900 targeted used facility 2018 Maturity New to2019 Bond leverage pay (5 years) Tim
Slide 23: Multiple Opportunities for Cost Savings and Enhanced Efficiency
MULTIPLE LabCorp Business Estimated Corporate Fully Purchasing Transaction 23 Realized and Optimization Overhead Cost & Accretive OPPORTUNITIES Covance Logistics Within Synergies Exceed to 3Have Years Adjusted to $100 a Shared FOR Million EPSCOST Focus in 2015 and on SAVINGS Be Before Operational Sy
Slide 24: Expands Customer Base
EXPANDS 30% Medicare 46% Care Medicaid 17% Standalone 7% 97% 3% Pro 29% Pharma/Biotech Private 32% Commercial 5% Clients 22% Source: 24 Forma Patients Managed 12%Patients Medicaid Company and Private Revenue LabCorp Covance CUSTOMER Medicare Care Food filings Mix Revenue & andDietary and BASE manage
Slide 25: Expands Geographic Reach
EXPANDS Standalone 92% 1% Other 9% Source: 11% 17% 46% Pro Distribution Euro Switzerland Zone 25 79% USA UK 4% Canada 5% 3% USA Forma 6%Zone Other Other 1% Company Geographic LabCorp Covance GEOGRAPHIC 5% of Revenue filings Geographic -and 2013 REACH management estimates.
Slide 26: Conclusion
Conclusion
Slide 27: Next Steps
NEXT Regulatory Expect Covance Will LabCorp Limited Integration 27 preserve STEPS Q1’15 Smooth overlap shareholder CEO has Focused approvals strong strong Closing Joe Integration will Herring track on Covance contribute vote Combining record to join brand; toofleadership seamless Best successful Pri
Slide 28: Compelling Benefits for Both Companies
COMPELLING Expands Increase Increases Increased Benefits Broadens Enhances Strengthens LabCorp’s Improves Aligns Leverages Reduces Provides Combined 28 with in to customer ability new strong, touch capability subject data fill-in LabCorp partnerships LabCorp’s Company expertise size LabCorp Covance
Slide 29: LabCorp to Acquire Covance
LabCorp to Acquire CREATING HEALTHCARE NOVEMBER THE 3, DIAGNOSTICS 2014 WORLD’S Covance LEADING COMPANY